A descriptive epidemiological study on the treatment options for head and neck cancer: Transition before and after approval of cetuximab
ConclusionThis study showed the current practices in concomitant medication used in chemoradiotherapy for HNC patients in Japan, the transition in anticancer drugs used before and after cetuximab approval, and the factors affecting the selection of concomitant drugs.
Source: Pharmacoepidemiology and Drug Safety - Category: Drugs & Pharmacology Authors: Shuhei Yamada,
Izumi Sato,
Koji Kawakami Tags: ORIGINAL REPORT Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Epidemiology | Erbitux | Head and Neck Cancer | Japan Health | Study